“Economic Costs of Diabetes in the U.S. 2017” (Published online in Diabetes Care Mar, 2018)

Per Brian Loveridge, MD; “Diabetes represents the most expensive medical condition in America. The prevalence continues to rise, with one out of two adults having either diabetes or pre-diabetes. Greater focus and attention is needed to address the complications of this epidemic that plagues both the U.S., and the world at large. We want to be a part of the solution with our physiologic insulin treatments.”

“ACP Recommends Less Intensive Glycemic Control Targets for Type 2 Diabetes” (Ann Internal Medicine, Mar 2018)

Per Brian Loveridge, MD; “The American College of Physicians revised its recommendations for blood sugar control in type 2 Diabetes from 6.5-7.0% HbA1c to 7.0-8.0%. These changes were made because tight control can lead to serious life-threatening low blood sugar episodes. Unfortunately, at higher ranges, it is well established that patients are at greater risk of developing diabetic complications (retinopathy, nephropathy, neuropathy, diabetic ulcers, etc.). Additional approaches are needed to reduce complications and help patients gain greater control. “

“Closing in on the Mechanism of Pulsatile Insulin Secretion” (Diabetes Mar 2018)

Per Brian Loveridge, MD; “The American Diabetes Association published this review article exploring the critical importance of physiologic insulin in carbohydrate metabolism. It is becoming increasingly apparent that when this signaling pathway breaks down, patients experience loss of insulin response, receptor lag, and decreasing receptor expression. We work with patients and providers to restore physiologic insulin, which in turn up-regulates metabolism and provides cells with the energy needed to function properly.”

“Pulsatile Insulin Secretion, Impaired Glucose Tolerance and Type 2 Diabetes” (Molecular Aspects Med, 2015)

Per Brian Loveridge, MD; “Detailed scientific exploration of how impaired insulin production leads to a breakdown in carbohydrate metabolism. In pre-diabetes, the body tries to overcome progressive insulin resistance by producing higher levels of insulin. Unfortunately, this creates a “toxic” environment for these receptors. With increasing insulin “resistance,” a patient goes from impaired glucose metabolism to type 2 diabetes. We aim to restore the natural physiology toward improved glycemic control.”

“Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care” (NEJM June 2018)

Per Brian Loveridge, MD; “Groundbreaking work in non-critical care type 2 diabetic patients, to use advanced technology to improve glycemic control. This resulted in significantly better glucose control than conventional therapy without a higher risk of low blood sugar events. Diabetes Relief likewise uses advances in technology, with the goal to restore physiologic insulin for tissue regeneration and healing in diabetes.”

Pin It on Pinterest